Inmune Bio (INMB) Cash & Current Investments (2017 - 2025)
Historic Cash & Current Investments for Inmune Bio (INMB) over the last 9 years, with Q3 2025 value amounting to $27.7 million.
- Inmune Bio's Cash & Current Investments fell 1734.02% to $27.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.7 million, marking a year-over-year decrease of 1734.02%. This contributed to the annual value of $20.9 million for FY2024, which is 4163.69% down from last year.
- According to the latest figures from Q3 2025, Inmune Bio's Cash & Current Investments is $27.7 million, which was down 1734.02% from $33.4 million recorded in Q2 2025.
- Inmune Bio's Cash & Current Investments' 5-year high stood at $84.5 million during Q3 2021, with a 5-year trough of $19.3 million in Q1 2025.
- For the 5-year period, Inmune Bio's Cash & Current Investments averaged around $44.7 million, with its median value being $41.8 million (2023).
- Its Cash & Current Investments has fluctuated over the past 5 years, first soared by 72059.8% in 2021, then plummeted by 4901.87% in 2024.
- Quarter analysis of 5 years shows Inmune Bio's Cash & Current Investments stood at $74.8 million in 2021, then tumbled by 30.29% to $52.2 million in 2022, then plummeted by 31.26% to $35.8 million in 2023, then plummeted by 41.64% to $20.9 million in 2024, then skyrocketed by 32.56% to $27.7 million in 2025.
- Its last three reported values are $27.7 million in Q3 2025, $33.4 million for Q2 2025, and $19.3 million during Q1 2025.